KR20100015304A - Ｃ형 간염 치료용 화합물 - Google Patents
Ｃ형 간염 치료용 화합물 Download PDFInfo
- Publication number
- KR20100015304A KR20100015304A KR1020097019018A KR20097019018A KR20100015304A KR 20100015304 A KR20100015304 A KR 20100015304A KR 1020097019018 A KR1020097019018 A KR 1020097019018A KR 20097019018 A KR20097019018 A KR 20097019018A KR 20100015304 A KR20100015304 A KR 20100015304A
- Authority
- KR
- South Korea
- Prior art keywords
- alkyl
- hcv
- cyclohexyl
- hydrogen
- methoxy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 CCC(C)S(N)(=*)=O Chemical compound CCC(C)S(N)(=*)=O 0.000 description 4
- RVEJNICLYSNMNX-UHFFFAOYSA-N CC(C)S(NC(c1ccc(c(C2CCCCC2)c(C2C(C3C4)=CC(OC)=CC2)[n]2CC34C(N3C4CN(C)CC3C4)=O)c2c1)=O)(=O)=O Chemical compound CC(C)S(NC(c1ccc(c(C2CCCCC2)c(C2C(C3C4)=CC(OC)=CC2)[n]2CC34C(N3C4CN(C)CC3C4)=O)c2c1)=O)(=O)=O RVEJNICLYSNMNX-UHFFFAOYSA-N 0.000 description 1
- OBQKOPFBXQPZHY-LFRRPJIKSA-N CC1=C2c(cc(cc3)OC)c3-c3c(C4CCCCC4)c(ccc(C(NS(N(C)C)(=O)=O)=O)c4)c4[n]3C[C@@]12C(N(C(CCC1)C(N2C)=O)C1C2=O)=O Chemical compound CC1=C2c(cc(cc3)OC)c3-c3c(C4CCCCC4)c(ccc(C(NS(N(C)C)(=O)=O)=O)c4)c4[n]3C[C@@]12C(N(C(CCC1)C(N2C)=O)C1C2=O)=O OBQKOPFBXQPZHY-LFRRPJIKSA-N 0.000 description 1
- PJBPDTNXKPZVJN-UHFFFAOYSA-N CCN(CC1C2)CC2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(C(C)C)(=O)=O)=O)=O Chemical compound CCN(CC1C2)CC2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(C(C)C)(=O)=O)=O)=O PJBPDTNXKPZVJN-UHFFFAOYSA-N 0.000 description 1
- HUCURYIIQZYNBU-IRVYNCSASA-N CCN(C[C@H]1C2)[C@H]2CN1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OCCN(C)S(NC(c5ccc(c(C6CCCCC6)c(-c(cc6)c(C7C8)cc6OC)[n]6CC78C(N(C7)[C@H](C8)C8[C@@H]7NC(OC(C)(C)C)=O)=O)c6c5)=O)(=O)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(N(C)C)(=O)=O)=O)=O Chemical compound CCN(C[C@H]1C2)[C@H]2CN1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OCCN(C)S(NC(c5ccc(c(C6CCCCC6)c(-c(cc6)c(C7C8)cc6OC)[n]6CC78C(N(C7)[C@H](C8)C8[C@@H]7NC(OC(C)(C)C)=O)=O)c6c5)=O)(=O)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(N(C)C)(=O)=O)=O)=O HUCURYIIQZYNBU-IRVYNCSASA-N 0.000 description 1
- IZPUCLUAOJYRDR-UHFFFAOYSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(O)=O)c2c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(O)=O)c2c1)=O)(=O)=O IZPUCLUAOJYRDR-UHFFFAOYSA-N 0.000 description 1
- FKYDPLWKRLECOK-UHFFFAOYSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C=O)cc2OC)[nH]2)c2c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C=O)cc2OC)[nH]2)c2c1)=O)(=O)=O FKYDPLWKRLECOK-UHFFFAOYSA-N 0.000 description 1
- KVAZYEIJQHGHMZ-VSBZUFFNSA-N CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N3C(CC4)CN(C)C4C3)=O)c2c1)=O)(=O)=O Chemical compound CN(C)S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c([C@@H]3C4)cc2OC)[n]2C[C@]34C(N3C(CC4)CN(C)C4C3)=O)c2c1)=O)(=O)=O KVAZYEIJQHGHMZ-VSBZUFFNSA-N 0.000 description 1
- SINFJPOLQZSHBM-UHFFFAOYSA-N CN(CC1)CCN1S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O Chemical compound CN(CC1)CCN1S(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O SINFJPOLQZSHBM-UHFFFAOYSA-N 0.000 description 1
- YRHGSGHFSAZQGC-UHFFFAOYSA-N CN(CC1CC2)C2CN1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CCCC1)(=O)=O)=O)=O Chemical compound CN(CC1CC2)C2CN1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CCCC1)(=O)=O)=O)=O YRHGSGHFSAZQGC-UHFFFAOYSA-N 0.000 description 1
- YCZNOFRNRXURSU-UHFFFAOYSA-N CN(CC1CC2)C2CN1C(C(C[n]1c2c3)=Cc(cccc4)c4-c1c(C1CCCCC1)c2ccc3C(OC)=O)=O Chemical compound CN(CC1CC2)C2CN1C(C(C[n]1c2c3)=Cc(cccc4)c4-c1c(C1CCCCC1)c2ccc3C(OC)=O)=O YCZNOFRNRXURSU-UHFFFAOYSA-N 0.000 description 1
- FISCEDZNVIQVOX-FQGHCGIQSA-N CN(C[C@@H]1COC2)C[C@@H]2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(CCC(F)(F)F)(=O)=O)=O)=O Chemical compound CN(C[C@@H]1COC2)C[C@@H]2N1C(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(CCC(F)(F)F)(=O)=O)=O)=O FISCEDZNVIQVOX-FQGHCGIQSA-N 0.000 description 1
- YSUYZYZAAKEFDF-UHFFFAOYSA-N CNS(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O Chemical compound CNS(NC(c1ccc(c(C2CCCCC2)c(-c(cc2)c(C3C4)cc2OC)[n]2CC34C(OC)=O)c2c1)=O)(=O)=O YSUYZYZAAKEFDF-UHFFFAOYSA-N 0.000 description 1
- JXNDZHVLICMRAK-UHFFFAOYSA-N COC(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(NCc1ccccc1)(=O)=O)=O)=O Chemical compound COC(C(C1)(C[n]2c3c4)C1c(cc(cc1)OC)c1-c2c(C1CCCCC1)c3ccc4C(NS(NCc1ccccc1)(=O)=O)=O)=O JXNDZHVLICMRAK-UHFFFAOYSA-N 0.000 description 1
- UGLSWHQLBQJMIP-UHFFFAOYSA-N COC(C1=Cc(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(N)(=O)=O)=O)c3)c3[n]2C1)=O Chemical compound COC(C1=Cc(cc(cc2)OC)c2-c2c(C3CCCCC3)c(ccc(C(NS(N)(=O)=O)=O)c3)c3[n]2C1)=O UGLSWHQLBQJMIP-UHFFFAOYSA-N 0.000 description 1
- CRELLSXEHXYFBV-UHFFFAOYSA-N COc(cc1)cc(C(C2)C2(C[n]2c3c4)C(O)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CC1)(=O)=O)=O Chemical compound COc(cc1)cc(C(C2)C2(C[n]2c3c4)C(O)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CC1)(=O)=O)=O CRELLSXEHXYFBV-UHFFFAOYSA-N 0.000 description 1
- CNSLHEYQHKYZPA-JRMGCUGESA-N COc(cc1)cc(C(C2)[C@@]2(C[n]2c3c4)C(N5C(CC6)CNC6C5)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CCC1)(=O)=O)=O Chemical compound COc(cc1)cc(C(C2)[C@@]2(C[n]2c3c4)C(N5C(CC6)CNC6C5)=O)c1-c2c(C1CCCCC1)c3ccc4C(NS(C1CCC1)(=O)=O)=O CNSLHEYQHKYZPA-JRMGCUGESA-N 0.000 description 1
- UXMGWMQTGJGCRY-PYRFXQKLSA-N C[C@@H]([C@H]1c(cc(cc2)OC)c2-c([n](C2)c3c4)c(C5CCCCC5)c3ccc4C(NS(N(C)C)(=O)=O)=O)[C@@]12C(N1C(C2)CN(C)C2C1)=O Chemical compound C[C@@H]([C@H]1c(cc(cc2)OC)c2-c([n](C2)c3c4)c(C5CCCCC5)c3ccc4C(NS(N(C)C)(=O)=O)=O)[C@@]12C(N1C(C2)CN(C)C2C1)=O UXMGWMQTGJGCRY-PYRFXQKLSA-N 0.000 description 1
- UGMYVFMYZWXHTG-QSDUKLCHSA-N C[C@@](CN(C)C[C@@]1(C)C2)(CN2C(C(C2)(C[n]3c4c5)C2c(cc(cc2)OC)c2-c3c(C2CCCCC2)c4ccc5C(NS(N(C)C)(=O)=O)=O)=O)C1O Chemical compound C[C@@](CN(C)C[C@@]1(C)C2)(CN2C(C(C2)(C[n]3c4c5)C2c(cc(cc2)OC)c2-c3c(C2CCCCC2)c4ccc5C(NS(N(C)C)(=O)=O)=O)=O)C1O UGMYVFMYZWXHTG-QSDUKLCHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Peptides Or Proteins (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US89488707P | 2007-03-14 | 2007-03-14 | |
| US60/894,887 | 2007-03-14 | ||
| US98947407P | 2007-11-21 | 2007-11-21 | |
| US60/989,474 | 2007-11-21 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20100015304A true KR20100015304A (ko) | 2010-02-12 |
Family
ID=39477552
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020097019018A Ceased KR20100015304A (ko) | 2007-03-14 | 2008-03-05 | Ｃ형 간염 치료용 화합물 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US7547690B2 (https=) |
| EP (1) | EP2118109B1 (https=) |
| JP (1) | JP5232178B2 (https=) |
| KR (1) | KR20100015304A (https=) |
| CN (1) | CN101657455B (https=) |
| AR (1) | AR065772A1 (https=) |
| AU (1) | AU2008226639B2 (https=) |
| BR (1) | BRPI0808763A2 (https=) |
| CA (1) | CA2681093A1 (https=) |
| CL (1) | CL2008000751A1 (https=) |
| CO (1) | CO6180426A2 (https=) |
| EA (1) | EA016614B1 (https=) |
| IL (1) | IL200905A0 (https=) |
| MX (1) | MX2009009473A (https=) |
| NZ (1) | NZ579342A (https=) |
| PE (1) | PE20090648A1 (https=) |
| TW (1) | TW200848058A (https=) |
| WO (1) | WO2008112473A1 (https=) |
| ZA (1) | ZA200906129B (https=) |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005049622A1 (ja) * | 2003-11-19 | 2005-06-02 | Japan Tobacco Inc. | ５－５員縮合複素環化合物及びそのｈｃｖポリメラーゼ阻害剤としての用途 |
| US20070049593A1 (en) * | 2004-02-24 | 2007-03-01 | Japan Tobacco Inc. | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor |
| US7659263B2 (en) | 2004-11-12 | 2010-02-09 | Japan Tobacco Inc. | Thienopyrrole compound and use thereof as HCV polymerase inhibitor |
| US7521443B2 (en) * | 2006-05-17 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7642251B2 (en) * | 2007-08-09 | 2010-01-05 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143243B2 (en) * | 2007-08-09 | 2012-03-27 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US7652004B2 (en) * | 2007-08-09 | 2010-01-26 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| KR20100108341A (ko) * | 2007-11-20 | 2010-10-06 | 브리스톨-마이어스 스큅 컴퍼니 | 시클로프로필 융합된 인돌로벤즈아제핀 ｈｃｖ ｎｓ5ｂ 억제제 |
| US8124601B2 (en) | 2007-11-21 | 2012-02-28 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| US8129367B2 (en) * | 2007-11-21 | 2012-03-06 | Bristol-Myers Squibb Company | Compounds for the treatment of Hepatitis C |
| ES2389994T3 (es) | 2007-12-24 | 2012-11-05 | Janssen R&D Ireland | Indoles macrocíclicos como inhibidores del virus de la hepatitis C |
| JP2011515486A (ja) * | 2008-03-27 | 2011-05-19 | ブリストル−マイヤーズ スクイブ カンパニー | Ｃ型肝炎の治療用化合物 |
| US8138171B2 (en) * | 2008-03-27 | 2012-03-20 | Bristol-Myers Squibb Company | Dioxolane and dioxolanone fused indolobenzadiazepine HCV NS5B inhibitors |
| WO2009120733A1 (en) * | 2008-03-27 | 2009-10-01 | Bristol-Myers Squibb Company | Pyrrolidine fused indolobenzadiazepine hcv ns5b inhibitors |
| US8133884B2 (en) * | 2008-05-06 | 2012-03-13 | Bristol-Myers Squibb Company | Compounds for the treatment of hepatitis C |
| US8143244B2 (en) * | 2009-02-26 | 2012-03-27 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| PH12012501068A1 (en) | 2009-12-07 | 2013-02-04 | Targacept Inc | 3,6-diazabicyclo [3.1.1] heptanes as neuronal nicotinic acetylcholine receptor ligands |
| US8716275B2 (en) * | 2011-10-20 | 2014-05-06 | Bristol-Myers Squibb Company | Compound for the treatment of hepatitis C |
| WO2014011863A1 (en) * | 2012-07-12 | 2014-01-16 | Targacept, Inc. | Method of treatment with 3-cyclopropylcarbonyl-3,6-diazabicyclo[3.1.1]heptane |
| EP3091022A3 (en) * | 2012-07-18 | 2016-12-14 | Bristol-Myers Squibb Holdings Ireland | Methods and intermediates for the preparation of (4bs,5ar)-12-cyclohexyl-n-(n,n-dimethylsulfamoyl)-3- methoxy-5a-((1r,5s)-3-methyl-3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-4b,5,5a,6-tetrahydrobenzo [3,4]cyclopropa[5,6]azepino[1,2-a]indole-9-carboxamide |
| KR20180125960A (ko) | 2016-03-15 | 2018-11-26 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 동물 해충을 방제하기 위한 치환된 술포닐 아미드 |
| TW201822637A (zh) | 2016-11-07 | 2018-07-01 | 德商拜耳廠股份有限公司 | 用於控制動物害蟲的經取代磺醯胺類 |
| CN110028510A (zh) * | 2019-05-22 | 2019-07-19 | 南京合巨药业有限公司 | 一种3-甲基-3,6-二氮杂-双环[3,1,1]庚烷二盐酸盐的制备方法 |
| US20220380318A1 (en) | 2019-11-07 | 2022-12-01 | Bayer Aktiengesellschaft | Substituted sulfonyl amides for controlling animal pests |
| US12274700B1 (en) | 2020-10-30 | 2025-04-15 | Accencio LLC | Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20090250T1 (hr) | 2004-02-24 | 2009-06-30 | Japan Tobacco | Kondenzirani heterociklički spojevi i njihova upotreba kao inhibitora hcv polimeraze |
| US7153848B2 (en) | 2004-08-09 | 2006-12-26 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| US7348425B2 (en) | 2004-08-09 | 2008-03-25 | Bristol-Myers Squibb Company | Inhibitors of HCV replication |
| EP1807403A2 (en) | 2004-10-26 | 2007-07-18 | Istituto di Richerche di Biologia Molecolare P. Angeletti S.p.A. | Tetracyclic indole derivatives as antiviral agents |
| GB0518390D0 (en) | 2005-09-09 | 2005-10-19 | Angeletti P Ist Richerche Bio | Therapeutic compounds |
| US7399758B2 (en) | 2005-09-12 | 2008-07-15 | Meanwell Nicholas A | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7473688B2 (en) | 2005-09-13 | 2009-01-06 | Bristol-Myers Squibb Company | Indolobenzazepine HCV NS5B inhibitors |
| US7456165B2 (en) | 2006-02-08 | 2008-11-25 | Bristol-Myers Squibb Company | HCV NS5B inhibitors |
| GB0608928D0 (en) | 2006-05-08 | 2006-06-14 | Angeletti P Ist Richerche Bio | Therapeutic agents |
| US7456166B2 (en) * | 2006-05-17 | 2008-11-25 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| US7521441B2 (en) | 2006-05-22 | 2009-04-21 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
| WO2007140200A2 (en) | 2006-05-25 | 2007-12-06 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors |
| JP5205370B2 (ja) | 2006-05-25 | 2013-06-05 | ブリストル−マイヤーズ スクイブ カンパニー | シクロプロピル縮合インドロベンゾアゼピンｈｃｖｎｓ５ｂ阻害剤 |
| US7452876B2 (en) | 2006-06-08 | 2008-11-18 | Bristol-Myers Squibb Company | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors |
-
2008
- 2008-02-28 US US12/039,239 patent/US7547690B2/en active Active
- 2008-03-05 NZ NZ579342A patent/NZ579342A/en not_active IP Right Cessation
- 2008-03-05 CA CA002681093A patent/CA2681093A1/en not_active Abandoned
- 2008-03-05 EA EA200901241A patent/EA016614B1/ru not_active IP Right Cessation
- 2008-03-05 BR BRPI0808763-6A patent/BRPI0808763A2/pt not_active IP Right Cessation
- 2008-03-05 KR KR1020097019018A patent/KR20100015304A/ko not_active Ceased
- 2008-03-05 MX MX2009009473A patent/MX2009009473A/es not_active Application Discontinuation
- 2008-03-05 WO PCT/US2008/055893 patent/WO2008112473A1/en not_active Ceased
- 2008-03-05 AU AU2008226639A patent/AU2008226639B2/en not_active Ceased
- 2008-03-05 CN CN200880008369XA patent/CN101657455B/zh not_active Expired - Fee Related
- 2008-03-05 EP EP08743684.6A patent/EP2118109B1/en not_active Not-in-force
- 2008-03-05 JP JP2009553689A patent/JP5232178B2/ja not_active Expired - Fee Related
- 2008-03-13 CL CL200800751A patent/CL2008000751A1/es unknown
- 2008-03-13 TW TW097108906A patent/TW200848058A/zh unknown
- 2008-03-13 PE PE2008000473A patent/PE20090648A1/es not_active Application Discontinuation
- 2008-03-14 AR ARP080101085A patent/AR065772A1/es not_active Application Discontinuation
-
2009
- 2009-09-03 ZA ZA2009/06129A patent/ZA200906129B/en unknown
- 2009-09-10 CO CO09097263A patent/CO6180426A2/es active IP Right Grant
- 2009-09-13 IL IL200905A patent/IL200905A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EA016614B1 (ru) | 2012-06-29 |
| EA200901241A1 (ru) | 2010-02-26 |
| NZ579342A (en) | 2011-07-29 |
| CN101657455B (zh) | 2013-02-06 |
| IL200905A0 (en) | 2010-05-17 |
| PE20090648A1 (es) | 2009-05-29 |
| AU2008226639A1 (en) | 2008-09-18 |
| ZA200906129B (en) | 2010-11-24 |
| JP2010521476A (ja) | 2010-06-24 |
| WO2008112473A1 (en) | 2008-09-18 |
| US20080227769A1 (en) | 2008-09-18 |
| JP5232178B2 (ja) | 2013-07-10 |
| EP2118109B1 (en) | 2014-11-26 |
| CO6180426A2 (es) | 2010-07-19 |
| BRPI0808763A2 (pt) | 2014-09-16 |
| AR065772A1 (es) | 2009-07-01 |
| CN101657455A (zh) | 2010-02-24 |
| CA2681093A1 (en) | 2008-09-18 |
| US7547690B2 (en) | 2009-06-16 |
| MX2009009473A (es) | 2009-09-15 |
| TW200848058A (en) | 2008-12-16 |
| CL2008000751A1 (es) | 2008-07-25 |
| EP2118109A1 (en) | 2009-11-18 |
| AU2008226639B2 (en) | 2012-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20100015304A (ko) | Ｃ형 간염 치료용 화합물 | |
| EP2099804B1 (en) | Compounds for the treatment of hepatitis c | |
| US7521441B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| EP2121697B1 (en) | Compounds for the treatment of hepatitis c | |
| EP2029606B1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| US7452876B2 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| EP2118108B1 (en) | Compounds for the treatment of hepatitis c | |
| EP2118110B1 (en) | Cyclopropyl fused indolobenzazepine hcv inhibitors | |
| EP2209789B1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| US8129367B2 (en) | Compounds for the treatment of Hepatitis C | |
| EP2121696B1 (en) | Compounds for the treatment of hepatitis c | |
| EP2215095B1 (en) | Cyclopropyl fused indolobenzazepine derivatives for the treatment of hepatitis c | |
| KR20070049635A (ko) | Ｈｃｖ 복제 저해제 | |
| EP2401280B1 (en) | Cyclopropyl fused indolobenzazepine hcv ns5b inhibitors | |
| AU2007253998A1 (en) | Cyclopropyl fused indolobenzazepine HCV NS5B inhibitors | |
| EP2114947B1 (en) | Indolobenzazepine derivatives for the treatment of hepatitis c | |
| CN101443336B (zh) | 环丙基稠合的[吲哚]并[苯并氮杂*]hcv ns5b抑制剂 | |
| ES2370121T3 (es) | Compuestos para el tratamiento de la hepatitis c. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
Patent event date: 20090911 Patent event code: PA01051R01D Comment text: International Patent Application |
|
| PG1501 | Laying open of application | ||
| A201 | Request for examination | ||
| PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20130304 Comment text: Request for Examination of Application |
|
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20140520 Patent event code: PE09021S01D |
|
| E601 | Decision to refuse application | ||
| PE0601 | Decision on rejection of patent |
Patent event date: 20141117 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20140520 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |